If this is your company, CONTACT US to activate Packbase™ software to build your portal.

    Aptar Pharma Launches First Metal-Free Highly Recyclable Nasal Spray Pump

    • Aptar Pharma

    Aptar Pharma, part of AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery systems, services and active material science solutions, today announces the launch of APF Futurity, its first metal-free, multidose nasal spray pump developed to deliver nasal saline and other comparable over-the-counter (OTC) formulations.

    Specifically designed for recyclability, APF Futurity is Aptar Pharma’s first highly recyclable nasal spray pump, having achieved a Class AA certification from cyclos-HTP for recycling streams in Europe[1]. APF Futurity is made from polyolefin materials with no metal parts or recycling disruptors, thereby minimizing separation efforts in recycling streams and supporting a higher quality of recyclates.

    Gael Touya, President, Aptar Pharma, commented, “As a leading provider of nasal spray pumps globally, the launch of APF Futurity is a significant step forward in our sustainability journey, underlining Aptar’s overall commitment to a more circular economy and meeting the global need for sustainable packaging solutions that are easy to recycle.”

    Part of Aptar Pharma’s Futurity sustainable solutions platform, APF Futurity meets a growing consumer need for increased access to recyclable products. In a study conducted by Aptar Pharma in 2022, 77% of respondents indicated that it was ‘important’ or ‘very important’ that the products they buy can be recycled[2]. When used in combination with a high-density polyethylene (HDPE) or polypropylene (PP) container bottle, a product with the APF Futurity pump can be conveniently recycled as one piece when empty after use, with no need to separate or detach any parts or materials before disposal, a key user benefit.

    Innovative design based on proven technology

    APF Futurity is based on Aptar Pharma’s proven Advanced Preservative Free (APF) technology platform, and has been initially developed to deliver multidose nasal saline and comparable OTC formulations. The innovative metal-free pump, for which patent protection has been filed, delivers precise and consistent dosing with soft actuation, with no trade-off on handling and performance.

    “APF Futurity is a game-changing innovation for the nasal spray pump industry and I am proud of our design and engineering team for meeting the challenge of designing this metal-free nasal pump,” stated Stefan Ritsche, President Global Market Development, Consumer Health Care, Aptar Pharma. “This is an important step in the transformation of our nasal spray portfolio to more sustainable solutions, and we look forward to bringing additional innovations of this kind to meet the need in the pharmaceutical industry.”

    Aptar’s commitment to sustainability

    Driven by our commitment to sustainable practices and products, with a focus on delivering transformative solutions that improve our world, Aptar continues to shape the drug delivery and consumer product dispensing markets.

    “Aptar continues to receive recognition for our sustainable product innovations, including the Institute of Packaging Professionals (IOPP) and WorldStar Global Packaging awards, and we were recently ranked #15 on Newsweek’s ‘America’s Most Responsible Companies‘ list,” added Christophe Marie, Product Sustainability Director, Aptar. “Aptar Pharma’s launch of APF Futurity is yet another sustainable product innovation that reinforces our pledge to care for our planet and reduce our environmental impact.”

    See also

    New FDA approved combination product with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multidose device is the delivery system for Glenmark’s Ryaltris™ nasal spray, which recently received New Drug Application (NDA) approval by the U.S. Food and Drug Administration. New FDA approved combination product for seasonal allergic rhinitis symptoms with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma granted exclusive license option by Pharmaxis to develop and promote high payload dry powder inhaler

    Aptar Pharma have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital. As part of the agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device and further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol.

    Noble and Aptar Pharma launch AdhereIT, a connected medical device solution for disease management adherence and onboarding patients

    Noble and Aptar Pharma are pleased to announce the launch of AdhereIT - a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms.

    Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield

    AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 masks) using their ActivShieldTM. The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic and this simple disinfecting process lets medical professionals reuse the masks after decontaminition.

    Aptar Pharma’s Nasal Unidose Device approved by US FDA for new nasal seizure rescue treatment

    Aptar Pharma has announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA as a rescue treatment for people with epilepsy aged six and older suffering from acute repetitive seizures. Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device which can deliver a formulation in an emergency situation quickly and easily.

    Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

    Aptar Pharma has announced that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH RELIEVA PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S. This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives.

    Aptar’s Nasal Unidose Device approved by US FDA

    AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

    Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

    AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

    Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

    Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

    • Juan Pablo Rueda
    • Product Info
    • English
    • Created 30 Jan 2023
    • Modified 30 Jan 2023
    • Hits 642